Subcutaneous immunoglobulin replacement therapy: The European experience

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 6, 2013, Pages 623-629

  Chapel, Helen ^a   Gardulf, Ann ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Immunoglobulin; Patient education; Primary immune deficiency; Self infusion; Subcutaneous

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN;

ANTIBIOTIC THERAPY; AUTOIMMUNITY; BACTERIAL INFECTION; BEHAVIOR CHANGE; BODY MASS; COMMON VARIABLE IMMUNODEFICIENCY; COST CONTROL; DRUG EFFICACY; DRUG SAFETY; ELECTROPHORESIS; EUROPE; FOLLOW UP; HEALTH CARE PERSONNEL; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFECTION PREVENTION; INFUSION RATE; LIFESTYLE; MULTICENTER STUDY (TOPIC); PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIMARY IMMUNE DEFICIENCY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; SUBSTITUTION THERAPY; TISSUE REACTION; UNSPECIFIED SIDE EFFECT; X LINKED AGAMMAGLOBULINEMIA;

AUTOIMMUNE DISEASES; EUROPE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS;

EID: 84889878773     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000013     Document Type: Review

References (39)

1. Bruton OC. Agammaglobulinaemia. Pediatrics 1952; 9:722-728.
2. Asherson GL, Hill KE, Citron KM. Primary immunodeficiency syndromes. Thorax 1970; 25:254-255.
3. Roord J, van der Meer JW, Kuis W, van Furth R. Treatment of antibody deficiency syndromes with subcutaneous infusion of gamma globulin. Birth Defects Orig Artic Ser 1983; 19:217-221.
4. Lucas M, Hugh-Jones K, Welby A, et al. Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. J Clin Immunol 2010; 30 (Suppl. 1):S84-S89.
5. Cohn E, Oncleym JL, Strong LE, et al. Chemical, clinical and immunological studies on the products of human plasma fractionation. 1. The characterisation of the protein fractions of human plasma. J Clin Invest 1944; 23:417-432.
6. Gardulf A, Hammarstrom L, Smith E. Home treatment of hypogammaglobulinaemia with SCIg by rapid infusion. Lancet 1991; 338:162-166.
7. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345:365-369.
8. Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiencies. Acta Paediatr Jpn 2007; 96:1474-1478. It is important to know that SCIg is well tolerated and acceptable in children.
9. Gardulf A, Nicolay U. Replacement IgG therapy and self therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:434-442. The quality-of-life data are important for convincing healthcare providers to support immunoglobulin replacement therapies.
10. Gardulf A, Bjo rvell H, Andersen V, et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21:917-927.
11. Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998; 112:341-346.
12. Remvig L, Andersen V, Hansen NE, Karle H. Prophylactic effect of selfadministered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: A triple-blind cross-over study comparing P-IgG levels of 3 g l-1 versus 6 g l-1. J Intern Med 1991; 229:73-77.
13. Thomas M, Brennan VM, Chapel H. Rapid subcutaneous immunoglobulin infusions in children. Lancet 1993; 342:1432-1433.
14. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998; 79:48-51.
15. Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gammaglobulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14:90-97. This study is pertinent to the pharmacokinetic studies required by the most regulators and licensing authorities.
16. Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol 2002; 104:237-241. Good data for convincing patients that speedy infusions are well tolerated.
17. Gardulf A, Bjo rvell H, Gustafson R, et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993; 92:200-204.
18. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936-942.
19. Gardulf A, Andersson E, Lindqvist M, et al. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol 2001; 21:150-154.
20. Chapel H, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 2:94-100. The first comparitive trial: important for European Medicines agency decision on equivalence of doses.
21. Borte M, Quinti I, Soresina A, et al. Efficacy and safety of subcutaneous vivaglobin replacement therapy in previously untreated patients with primary immunodeficiency: A prospective, multicenter study. J Clin Immunol 2011; 31:952-961. SCIg can be used in previously untreated patients.
22. Gustafson R, Gardulf A, Hansen S, et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008; 152:274-279. This study confirms the equivalence data for dosing and demonstrates the various pharmacokinetic measurements available.
23. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354-1360. This study demonstrates the importance of individual IgG trough levels in infection prevention.
24. Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody defciencies: A systematic review. Clin Exp Immunol 2007; 149:410-423.
25. Nahirniak S, Hume H. Guidelines for the use of IVIG for primary immune deficiency and solid organ transplantation. Transfus Med Rev 2010; 24 (Suppl. 1).
26. Tang M, Kemp A, Loh R, et al. APPIG Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency. Asia Pacific Immunoglobulins in Immunology Expert Group Inc (APIIEG). 1st ed. 2008.
27. Gelfand E, Ochs HD, Shearer WT. Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J Allergy Clin Immunol 2013; 131:1001-1005.
28. Ugazio A, Duse M, Re R, et al. Subcutaneous infusion of gammaglobulins in management of agammaglobulinaemia. Lancet 1982; 319:226.
29. Ochs H, Gupta S, Kiessling P, et al. Safety and efficacy of selfadministered subcutaneous immunoglobulin in patients with primary immunodeficiency disease. J Clin Immunol 2006; 26:265-273.
30. Ochs H, Lee ML, Fischer SH, et al. Self-infusion of intravenous immunoglobulin by immunodeficient patients at home. J Infect Dis 1987; 56:652-654. The first publication of self-infusion of immunoglobulin in replacement therapy.
31. Chapel HBV, Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol 1988; 73:160-162.
32. Brennan VM, Salomé -Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 PAD patients receiving IVIg. Clin Exp Immunol 2003; 133:247-251. This study confirms the safety of self-infusion of therapeutic immunoglobulin in primary antibody deficiency patients.
33. Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009; 158 (Suppl. 1):51-59.
34. Shapiro R. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr Allergy Immunol 2013; 24:49-53. The first publication to indicate that no special equipment is needed, so important for cost-effectiveness.
35. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med 2013; 23:55-60.Confirmation of reduced costs: important for healthcare providers.
36. Wagner E, Austin B, von Korff M. Organizing care for patients with chronic illness. Milbank Q 1996; 74:511-543.
37. Vickers P, Gardulf A, Warner A. The role of the nurses in recognizing and caring for patients with primary immunodeficiencies. Pharm Policy Law 2008; 10:43-50.
38. Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008; 28:370-378.
39. Chapel H, Brennan V, Delson E. Immunoglobulin replacement therapy by selfinfusion at home. Clin Exp Immunol 1988; 73:160-162.